JOSÉ LUIS
CABRIADA NUÑO
Researcher to 2022
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublications in collaboration with researchers from Complexo Hospitalario Universitario de Santiago (24)
2023
-
Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
-
Increased use of healthcare resources during the preclinical period of inflammatory bowel disease
Digestive and Liver Disease
2020
-
Early microscopic findings in preclinical inflammatory bowel disease
Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
-
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
Therapeutic Advances in Gastroenterology, Vol. 12
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
-
Granulocyte–monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis
Scandinavian Journal of Gastroenterology, Vol. 54, Núm. 4, pp. 459-464
-
The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
Journal of Clinical Apheresis, Vol. 34, Núm. 6, pp. 680-685
2018
-
Characteristics and Progression of Preclinical Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466
-
Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients’ point of view
Gastroenterologia y Hepatologia, Vol. 41, Núm. 7, pp. 423-431
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800